<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine</h1>
  <ul>
<li>Result: Fair Value of $188.19 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts.</li>
<li>Most Popular Narrative: 2.5% Undervalued The most followed narrative sees Quest Diagnostics trading below its estimated fair value, with analysts projecting modest upside from current levels.</li>
<li>This announcement arrives at a moment when Quest Diagnostics is already showing positive stock momentum, with shares returning 21% over the past year and nearly matching that gain year-to-date.</li>
<li>It offers actionable guidance that could make prescribing both safer and more effective.</li>
<li>This supports long-term earnings power.</li>
<li>Curious about why experts think there is still room for this stock to climb?</li>
<li>Want to discover the underlying numbers and key assumptions driving this price target?</li>
</ul>
<p><a href="https://finance.yahoo.com/news/quest-diagnostics-dgx-assessing-valuation-141429190.html">Source</a> · 2025-09-08T14:14:29+00:00</p>
</body>
</html>